

Title (en)

VASOPRESSIN PATHWAY POLYMORPHISMS AS INDICATORS OF SUBJECT OUTCOME IN CRITICALLY ILL SUBJECTS

Title (de)

VASOPRESSIN-PFAD-POLYMORPHIEN ALS INDIKATOREN DES PATIENTENERGEBNISSES IN SCHWER KRANKEN PATIENTEN

Title (fr)

POLYMORPHISMES DE LA VOIE DE SIGNALISATION DE LA VASOPRESSINE EN TANT QU'INDICATEURS DE L'ÉVOLUTION DE L'ÉTAT DE SUJETS CHEZ DES SUJETS GRAVEMENT ATTEINTS

Publication

EP 1984546 A4 20090923 (EN)

Application

EP 07719352 A 20070124

Priority

- CA 2007000111 W 20070124
- US 76132806 P 20060124
- US 79515706 P 20060427

Abstract (en)

[origin: WO2007085087A1] The invention provides methods, nucleic acids, compositions and kits for predicting a subject's response to treatment with one or more vasopressin receptor agonists to identify subjects having a greater benefit from treatment with vasopressin receptor agonist(s). The method generally comprises determining a vasopressin pathway associated gene polymorphism genotype(s) of a subject for one or more polymorphisms in the these genes, comparing the determined genotype with known genotypes for the polymorphism that correspond with an improved response genotype to identify potential subjects having an inflammatory condition who are more likely to benefit from treatment with a vasopressin receptor agonist and subsequent to treatment recover from the inflammatory condition. The invention also provides for methods of treating such subjects with vasopressin receptor agonists based on the subject's genotype.

IPC 8 full level

C40B 40/06 (2006.01); **A61K 31/00** (2006.01); **A61K 38/00** (2006.01); **A61K 38/22** (2006.01); **A61P 29/00** (2006.01); **C07H 21/00** (2006.01); **C07K 14/575** (2006.01); **C12N 15/16** (2006.01); **C12P 19/34** (2006.01); **C12Q 1/00** (2006.01); **C12Q 1/68** (2006.01); **C40B 30/00** (2006.01)

CPC (source: EP)

A61K 38/095 (2018.12); **A61P 1/04** (2017.12); **A61P 1/16** (2017.12); **A61P 1/18** (2017.12); **A61P 3/10** (2017.12); **A61P 7/06** (2017.12); **A61P 9/00** (2017.12); **A61P 9/10** (2017.12); **A61P 11/00** (2017.12); **A61P 11/08** (2017.12); **A61P 13/02** (2017.12); **A61P 13/12** (2017.12); **A61P 25/00** (2017.12); **A61P 29/00** (2017.12); **A61P 31/00** (2017.12); **A61P 31/16** (2017.12); **A61P 31/18** (2017.12); **A61P 33/06** (2017.12); **A61P 37/06** (2017.12); **C12Q 1/6883** (2013.01); **C12Q 2600/106** (2013.01); **C12Q 2600/118** (2013.01); **C12Q 2600/136** (2013.01); **C12Q 2600/156** (2013.01); **C12Q 2600/172** (2013.01); **Y02A 50/30** (2017.12)

Citation (search report)

- [X] WO 2005087789 A1 20050922 - UNIV BRITISH COLUMBIA [CA], et al
- [A] US 2004033582 A1 20040219 - EDMONDS MANLING-MA [US], et al
- [A] WO 2005038462 A1 20050428 - SUNTORY LTD [JP], et al
- [A] SUZUKI YUKA ET AL: "Possible role of placental leucine aminopeptidase in the antiproliferative effect of oxytocin in human endometrial adenocarcinoma", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. 4, 1 April 2003 (2003-04-01), pages 1528 - 1534, XP002304844, ISSN: 1078-0432
- See references of WO 2007085087A1

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2007085087 A1 20070802; AU 2007209725 A1 20070802; CA 2638773 A1 20070802; EP 1984546 A1 20081029; EP 1984546 A4 20090923; JP 2009523456 A 20090625; MX 2008009654 A 20090115

DOCDB simple family (application)

CA 2007000111 W 20070124; AU 2007209725 A 20070124; CA 2638773 A 20070124; EP 07719352 A 20070124; JP 2008551611 A 20070124; MX 2008009654 A 20070124